Okyo Pharma LTD (OKYO) — 6-K Filings

All 6-K filings from Okyo Pharma LTD. Browse 48 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (48)

OKYO Pharma Files 6-K Report — Apr 7, 2026 Risk: low
OKYO Pharma Ltd filed a Form 6-K on April 7, 2026, reporting information as a foreign issuer. The filing includes the 6-K form itself, an exhibit EX-99.1, and a
OKYO Pharma Rings Nasdaq Opening Bell — Dec 19, 2025 Risk: low
On December 19, 2025, OKYO Pharma Ltd announced that Executive Chairman and Founder, Gabriele Cerrone, along with the management team, will ring the Opening Bel
6-K Filing — Dec 15, 2025
6-K Filing — Dec 11, 2025
6-K Filing — Dec 3, 2025
6-K Filing — Nov 21, 2025
6-K Filing — Nov 18, 2025
OKYO Pharma CEO to Speak at BIO-Europe Conference — Oct 29, 2025 Risk: low
On October 29, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present at the 33rd Annual BIO-Europe partnering conference in Vienna, A
OKYO Pharma: Chairman's Entity Buys 210K Shares — Oct 16, 2025 Risk: low
On October 16, 2025, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone,
OKYO Pharma Starts 100-Patient Trial for Urcosimod — Sep 22, 2025 Risk: medium
On September 22, 2025, OKYO Pharma Ltd announced the initiation of a 100-patient, multi-center clinical trial for Urcosimod to treat Neuropathic Corneal Pain. T
OKYO Pharma Secures $1.9M Non-Dilutive Funding — Jul 17, 2025 Risk: medium
On July 17, 2025, OKYO Pharma LTD announced it secured $1.9 million in non-dilutive funding. This capital injection is designated to advance the company's resea
OKYO Pharma Announces Positive Phase 2 Data for Urcosimod — Jul 16, 2025 Risk: medium
On July 16, 2025, OKYO Pharma Ltd announced positive top-line data from its 18-patient Phase 2 trial for urcosimod (formerly OK-101) to treat Neuropathic Cornea
OKYO Pharma CEO to Present on Urcosimod at Bio International Convention — Jun 11, 2025 Risk: low
On June 11, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present on the development of urcosimod at the Bio International Convention
OKYO Pharma CEO to Present at GPCR Drug Discovery Summit — May 19, 2025 Risk: low
On May 19, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, Ph.D., will present at the 4th Annual GPCRs-Targeted Drug Discovery Summit in Boston, MA
OKYO Pharma's Urcosimod Gets FDA Fast Track for Pain — May 1, 2025 Risk: medium
On May 1, 2025, OKYO Pharma Ltd announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its drug candidate, urcosimod.
OKYO Pharma Accelerates Urcosimod Development for NCP — Apr 30, 2025 Risk: medium
OKYO Pharma Ltd announced on April 30, 2025, that it will accelerate the clinical development of its drug urcosimod for treating NCP. This decision follows an a
OKYO Pharma's Urcosimod Shows Long-Term Stability — Mar 31, 2025 Risk: low
On March 31, 2025, OKYO Pharma Ltd announced that its drug candidate, urcosimod (formerly OK-101), has demonstrated stability for over two and a half years when
OKYO Pharma Seeks FDA Fast Track for Neuropathic Pain Drug — Mar 10, 2025 Risk: medium
On March 10, 2025, OKYO Pharma Ltd announced it has filed an application with the U.S. Food and Drug Administration (FDA) for Fast Track designation for its dru
OKYO Pharma's OK-101 Asset Named Urcosimod — Feb 12, 2025 Risk: low
On February 12, 2025, OKYO Pharma Ltd announced that its lead asset, OK-101, has been officially assigned the United States Adopted Name (USAN) "urcosimod". Thi
OKYO Pharma CEO Buys Shares — Jan 31, 2025 Risk: low
On January 31, 2025, OKYO Pharma Ltd announced that its CEO, Gary S. Jacob, purchased 10,000 ordinary shares on NASDAQ at $1.04 per share. This purchase was mad
OKYO Pharma Ltd Reports H1 2024 Financials and Business Update — Jan 29, 2025 Risk: low
OKYO Pharma Ltd announced its financial results for the six-month period ending September 30, 2024, on January 29, 2025. The company, headquartered in London, a
OKYO Pharma Secures $1.4M Non-Dilutive Funding — Jan 22, 2025 Risk: low
On January 22, 2025, OKYO Pharma Ltd announced it has secured $1.4 million in non-dilutive funding. This capital infusion will support the advancement of the co
OKYO Pharma CEO to Speak at BTIG Ophthalmology Day — Nov 26, 2024 Risk: low
OKYO Pharma Ltd announced on November 26, 2024, that its CEO, Gary S. Jacob, Ph.D., will participate in the 4th Annual Virtual BTIG Ophthalmology Day on Decembe
OKYO Pharma to Present at Ocular Surface Conference — Oct 30, 2024 Risk: low
OKYO Pharma Ltd announced on October 30, 2024, that its management team will present at the 10th International Tear Film & Ocular Surface Society Conference in
OKYO Pharma Doses First Patient in OK-101 Phase 2 NCP Trial — Oct 23, 2024 Risk: medium
On October 23, 2024, OKYO Pharma Ltd announced that the first patient has been dosed in its Phase 2 clinical trial for topical ocular OK-101, a treatment for Ne
OKYO Pharma Starts Phase 2 Trial for OK-101 — Oct 16, 2024 Risk: medium
On October 16, 2024, OKYO Pharma Ltd announced the commencement of patient screening and recruitment for a Phase 2 clinical trial of its drug OK-101. This trial
OKYO Pharma: Chairman's Entity Buys 50,000 Shares — Sep 10, 2024 Risk: medium
On September 10, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone
OKYO Pharma: Chairman's associate buys 80,000 shares — Sep 5, 2024 Risk: low
On September 5, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity associated with Executive Chairman Gabriele Cerrone, acquired 80,000 or
OKYO Pharma Secures US Patent for Dry Eye Treatment — Aug 27, 2024 Risk: low
On August 27, 2024, OKYO Pharma Ltd announced the grant of U.S. Patent No. 12,053,501, issued on August 6th, for "Methods for Treating Symptoms of Dry Eye Disea
OKYO Pharma: Chairman's associate buys 50,000 shares — Aug 23, 2024 Risk: low
On August 23, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity associated with Executive Chairman Gabriele Cerrone, purchased 50,000 ord
OKYO Pharma: Chairman's Entity Buys 35,000 Shares — Aug 21, 2024 Risk: low
On August 21, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity with a beneficial interest held by Executive Chairman Gabriele Cerrone, p
OKYO Pharma to Participate in H.C. Wainwright Ophthalmology Conference — Aug 15, 2024 Risk: low
OKYO Pharma Ltd announced on August 15, 2024, that it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The conference is sch
OKYO Pharma Secures Key European Patent for Chemerin Analogs — Aug 6, 2024 Risk: medium
On August 6, 2024, OKYO Pharma Ltd announced the grant of a key European Patent for "Compositions Comprising Chemerin Analogs and Methods of Use." Raj Patil, Ch
OKYO Pharma to Start Phase 2 Trial for Neuropathic Corneal Pain — Jul 11, 2024 Risk: medium
OKYO Pharma Ltd announced on July 11, 2024, its intention to initiate a Phase 2 clinical trial for its drug candidate OK-101 to treat neuropathic corneal pain.
OKYO Pharma Ltd Files New Investor Presentation — Jul 10, 2024 Risk: low
On July 10, 2024, OKYO Pharma Ltd announced the filing of a new investor presentation. This presentation is furnished as Exhibit 99.1 to their Form 6-K filing w
OKYO Pharma to Present at May Investor Conferences — May 8, 2024 Risk: low
OKYO Pharma Ltd announced on May 8, 2024, that it will be participating in two investor conferences in May 2024. The company, located at 55 Park Lane, London, w
OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data — Apr 30, 2024 Risk: medium
OKYO Pharma Ltd announced on April 30, 2024, that it will present Phase 2 data for its dry eye disease drug, OK-101, at the Dry Horizons Symposium on May 3, 202
OKYO Pharma Reschedules KOL Event for OK-101 Phase 2 Trial Results — Apr 9, 2024 Risk: medium
OKYO Pharma Ltd announced on April 8, 2024, that it is rescheduling its Key Opinion Leader (KOL) event. This event was intended to present comprehensive detaile
OKYO Pharma Ltd. Files 6-K with SEC — Apr 4, 2024 Risk: low
OKYO Pharma Ltd. filed a Form 6-K on April 4, 2024, to report information as a foreign private issuer. The filing indicates the company is based in London, UK,
OKYO Pharma to Present OK-101 Phase 2 Dry Eye Data — Apr 2, 2024 Risk: medium
OKYO Pharma Ltd announced on April 2, 2024, that it will present Phase 2 data for its dry eye disease treatment, OK-101, at Eyecelerator 2024. This event is a p
OKYO Pharma Ltd Reports Interim Results — Mar 29, 2024 Risk: low
OKYO Pharma Ltd announced its interim results for the six months ended September 30, 2023, on March 29, 2024. The company, headquartered in London, filed a Form
OKYO Pharma's OK-101 Trial Shows Success in Dry Eye Disease — Mar 22, 2024 Risk: medium
On March 22, 2024, OKYO Pharma Ltd announced that its Phase 2 trial for OK-101 in treating Dry Eye Disease achieved statistical significance. The drug demonstra
OKYO Pharma to Host KOL Event for OK-101 Phase 2 Data — Mar 21, 2024 Risk: medium
OKYO Pharma Ltd announced on March 21, 2024, that it will host a Key Opinion Leader (KOL) event on April 9th, 2024, at 12:00 PM ET. The event will focus on disc
OKYO Pharma to Release Dry Eye Trial Data March 22 — Mar 20, 2024 Risk: medium
OKYO Pharma Ltd announced on March 20, 2024, that it will release new efficacy data from its Phase 2 trial of OK-101 for dry eye disease on March 22, 2024. The
OKYO Pharma's OK-101 Cleared by FDA for Neuropathic Corneal Pain IND — Feb 9, 2024 Risk: medium
OKYO Pharma Ltd. announced on February 9, 2024, that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for
OKYO Pharma Adds Top Ophthalmologists to Scientific Advisory Board — Jan 31, 2024
OKYO Pharma Ltd. announced on January 31, 2024, that three distinguished ophthalmologists, Victor Perez, M.D., Anat Galor, M.D., and Mark Milner, M.D., have joi
OKYO Pharma's OK-101 Hits Key Endpoints in Phase 2 Dry Eye Trial — Jan 8, 2024
OKYO Pharma Ltd. announced on January 8, 2024, that its drug candidate, OK-101, successfully met both sign and symptom endpoints with statistical significance i
OKYO Pharma to Present at Biotech Showcase, Seek Partnerships — Jan 5, 2024
OKYO Pharma Ltd. announced on January 5, 2024, that its management team will present at the Biotech Showcase in San Francisco from January 8-10, 2024. They will

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX